Type 2 Diabetes — The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes
Citation(s)
Awad N, Gagnon M, Messier C The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. Review.
Brand-Miller J, Hayne S, Petocz P, Colagiuri S Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2003 Aug;26(8):2261-7.
Ingwersen J, Defeyter MA, Kennedy DO, Wesnes KA, Scholey AB A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. Appetite. 2007 Jul;49(1):240-4. Epub 2007 Jan 16.
Kaplan RJ, Greenwood CE, Winocur G, Wolever TM Cognitive performance is associated with glucose regulation in healthy elderly persons and can be enhanced with glucose and dietary carbohydrates. Am J Clin Nutr. 2000 Sep;72(3):825-36.
Papanikolaou Y, Palmer H, Binns MA, Jenkins DJ, Greenwood CE Better cognitive performance following a low-glycaemic-index compared with a high-glycaemic-index carbohydrate meal in adults with type 2 diabetes. Diabetologia. 2006 May;49(5):855-62. Epub 2006 Mar 1.
Smith MA, Foster JK The impact of a high versus a low glycaemic index breakfast cereal meal on verbal episodic memory in healthy adolescents. Nutr Neurosci. 2008 Oct;11(5):219-27. doi: 10.1179/147683008X344110.
Stewart R, Liolitsa D Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med. 1999 Feb;16(2):93-112. Review.
Wong PC, Parsons LM, Martinez M, Diehl RL The role of the insular cortex in pitch pattern perception: the effect of linguistic contexts. J Neurosci. 2004 Oct 13;24(41):9153-60.
The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
